Welcome to our comprehensive resource on the powerful Simcyp Plugin for Excel, a cutting-edge tool that integrates the robust biosimulation capabilities of Simcyp software with the versatility of Microsoft Excel. By harnessing physiological based pharmacokinetics (PBPK) modeling, this plugin is revolutionizing translational research, offering predictive insights into drug pharmacokinetics and pharmacodynamics. On this page, we delve into the essence of Simcyp, explore the seamless synergy between Simcyp and Excel, highlight common use cases for the plugins, and answer your frequently asked questions. Discover how this valuable tool is accelerating drug development from pre-IND to post-marketing, assisting in clinical trial design, and extending its benefits to special populations and novel routes of administration.
The Simcyp Simulator is a sophisticated software tool known as a physiologically-based pharmacokinetic (PBPK) modeling and simulation platform. It serves as a predictive framework to forecast how drugs might behave in various clinical trial scenarios, including those that have not been physically tested. The software utilizes virtual populations to replicate drug performance in clinical studies, providing insights into dosing and safety that can potentially reduce the need for actual clinical trials.
As a service, Simcyp offers a wide array of applications including determination of first-in-human dosing, optimization of clinical study designs, evaluation of new drug formulations, and making predictions about drug-drug interactions (DDIs). It is capable of assessing a diverse range of pharmaceuticals, from small molecules and biologics to antibody-drug conjugates (ADCs), generics, and new modality drugs. Simcyp plays a critical role in predicting dosing for different patient populations, including pediatric, geriatric, patients with organ impairment, and those from various ethnic backgrounds and disease states.
From a data perspective, Simcyp integrates systems data, drug data, and trial design information to model drug behavior in the body's tissues and organs. It does so by considering each organ as one or several physiological compartments. The software is equipped with unique genetic, physiological, and epidemiological databases that enable the simulation of virtual populations with diverse demographics and health conditions. This versatility allows Simcyp to be a valuable asset for clinical trials, regulators, and consultants who are involved in drug-drug interaction simulations, absorption modeling, and dosing for special populations.
The Simcyp Excel plugin is a mechanistic physiologically-based pharmacokinetic (PBPK) modeling tool designed to simulate how drugs behave in different body tissues. Utilizing genetic, physiological, and epidemiological databases, it allows for the simulation of virtual populations. This tool has contributed to informing over 250 label claims for more than 85 novel drug approvals by the US Food and Drug Administration (FDA), achieved virtually through PBPK modeling and simulation without the need for clinical trials.
The Simcyp Excel plugin serves as a sophisticated PBPK modeling platform, acknowledged by regulatory agencies such as the EMA and PMDA. It aids in determining first-in-human dosing, optimizing clinical study designs, and evaluating new drug formulations. Additionally, it supports setting doses in untested populations, performing virtual bioequivalence analyses, and predicting drug-drug interactions. The plugin is instrumental in predicting dosing recommendations for different patient populations, demonstrating its utility in the pharmaceutical industry as the most sophisticated PBPK platform.
The Simcyp PBPK Simulator is used for determining first-in-human dosing, optimizing clinical study design, evaluating new drug formulations, predicting drug-drug interactions (DDIs), and predicting dosing recommendations for patients with different demographics.
Yes, the Simcyp PBPK Simulator is used to replace the need for some clinical trials and has been used to inform drug labels for approximately 300 drugs.
Yes, the Simcyp Simulator has been adopted by 11 global regulatory agencies, including the FDA, EMA, and PMDA.
Simcyp has unique modules such as Simcyp Pediatric for modeling drug performance and dosing in children, Simcyp Cardiac Safety Simulator (CSS) for assessing the pro-arrhythmic potency of drugs, and Simcyp Long Acting Injectable (LAI) for designing experiments for LAI drug delivery.
Simcyp workshops are designed to teach participants how to simulate and predict pharmacokinetics and pharmacodynamics, improve clinical study design, reduce development costs and time, and improve the quality of regulatory submissions.